Analyst Ratings For Allergan plc (NYSE:AGN)
Today, Barclays raised its price target on Allergan plc (NYSE:AGN) to $188.00 per share.
There are 15 Hold Ratings, 7 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Allergan plc (NYSE:AGN) is Hold with a consensus target price of $178.0967 per share, a potential 11.67% upside.
Some recent analyst ratings include
- 8/7/2019-Allergan plc (NYSE:AGN) gets downgraded to Neutral by Guggenheim
- 7/18/2019-Allergan plc (NYSE:AGN) had its Outperform ➝ Market Perform rating reiterated by Svb Leerink with a $188.00 price target
- 7/18/2019-Allergan plc (NYSE:AGN) gets downgraded to Market Perform by Leerink Swann with a price target of $188.00
- 7/16/2019-Allergan plc (NYSE:AGN) gets downgraded to Market Perform by Sanford C. Bernstein with a price target of $166.08
- On 3/7/2019 Brent L Saunders, Chairman, bought 1,760 with an average share price of $143.67 per share and the total transaction amounting to $252,859.20.
- On 11/16/2018 Matthew M. Walsh, CFO, bought 1,000 with an average share price of $157.00 per share and the total transaction amounting to $157,000.00.
- On 9/6/2018 Christopher J. Coughlin, Director, bought 10,000 with an average share price of $190.64 per share and the total transaction amounting to $1,906,400.00.
- On 8/30/2018 Joseph H. Boccuzi, Director, bought 900 with an average share price of $190.59 per share and the total transaction amounting to $171,531.00.
- On 5/17/2018 William Meury, EVP, sold 24,425 with an average share price of $154.59 per share and the total transaction amounting to $3,775,860.75.
- On 3/15/2018 Maria Teresa Hilado, Insider, bought 895 with an average share price of $167.39 per share and the total transaction amounting to $149,814.05.
- On 3/8/2018 Brent L. Saunders, CEO, bought 3,300 with an average share price of $152.53 per share and the total transaction amounting to $503,349.00.
About Allergan plc (NYSE:AGN)
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. Read More…
Recent Trading Activity for Allergan plc (NYSE:AGN)
Shares of Allergan plc closed the previous trading session at 159.49 −1.14 0.71% with 7319800 shares trading hands.